Company / PP&E (Net)
Sunshine Biopharma Inc. PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$557.4K
FY2025
5-year range
$7.1K / $557.4K
FY2021-FY2025
Trend
+2.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
PP&E (Net) has fluctuated over the past 10 years, ranging from $5,944 in FY2016 to $557,370 in FY2025.
Based on SEC 10-K filings.
$557,370 in FY2025 with a 5-year CAGR of +95.5%.
Improved from $365,868 to $557,370 over the past 2 years.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +12.2%
- 5-Year CAGR
- +95.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +95.5%, indicating consistent growth.
- In FY2025, pp&e (net) increased 2.1% year-over-year.
- Lowest pp&e (net) in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $557.4K | +2.1% |
| FY2024 | $546.1K | +49.2% |
| FY2023 | $365.9K | -7.2% |
| FY2022 | $394.2K | +5483.5% |
| FY2021 | $7.1K | -63.8% |
| FY2020 | $19.5K | -39.8% |
| FY2019 | $32.5K | -88.0% |
| FY2018 | $269.4K | +349.0% |
| FY2017 | $60.0K | +909.4% |
| FY2016 | $5.9K | +37.8% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026